Melissa Alvarez, MD@malvarez_md

Aug 13

American College of Cardiology

@ACCinTouch

Aug 12

Do you know a student interested in science, health care or cardiology? Encourage them to apply for ACC’s Young Scholars Program. 📝 Applications are now open for grades 9-11 students in Boston, Dallas, Honolulu, Irvine, & Omaha.

⏰ Learn more 👉 bit.ly/4yR3JVk

Melissa Alvarez, MD@malvarez_md

Jun 28

Leah Pierson

@leah_pierson

Jun 27

The residency selection process incentivizes medical students, writ large, to do research.

This is bad because:

1) Most people go to medical school to become doctors, not researchers. We should let them do the socially valuable thing they want to do and are presumably best at.

Melissa Alvarez, MD@malvarez_md

Apr 6

Rawan Amir@RawanAAmir

Apr 5

Still not over this 🫀

The first ever @CardioNerds 5K 🏃🏻‍♀️

6:45 AM start 🕖
Amazing turnout 🔥
Incredible energy ✨

Thank you to everyone who showed up 🙏🏻

Putting this together meant a lot 🥹

Already thinking about next year 🤍
#ACC #NOLA #Cardiotwitter

Melissa Alvarez, MD@malvarez_md

Apr 6

Kamala Tamirisa MD@KTamirisaMD

Apr 6

#ACCWIC
@txchapteracc
@ACCinTouch

Join @ManthaYogamaya
#TCACC @SamRRazaMD with @WilliamZoghbi @DrMarthaGulati

📕: @melrobbins #LetThem

@dr_chebrolu @arunima_misra
@shelleyhallmd @NadeenFaza @RajendraPShahMD @ShadenKhalaf @malvarez_md @CASivaram1 @HeartOTXHeartMD

Melissa Alvarez, MD@malvarez_md

Mar 31

Leah Kosyakovsky@leahkosyakovsky

Mar 31

So proud of our former @ACCinTouch Young Scholar @AzmerKhan11, who has been coming to ACC EVERY YEAR since his cohort in 2023 to present his own structural research. AND he's now a first year medical student!

He's an incredible role model for all our Scholars to come! #ACC26

Melissa Alvarez, MD@malvarez_md

Mar 30

Luai Tabaza@Tabaza

Mar 30

How the data emerging from #ACC26 will shape my thinking

No single trial should redefine practice. Decisions remain anchored in the totality of evidence and the realities we face at the bedside.

Axial mechanical support trials including PROTECT IV trial and CHIP-BCIS3 trial reinforce that high risk PCI is not a uniform entity. The signal is not universal. The opportunity lies in identifying the specific hemodynamic and anatomic subsets most likely to benefit from upfront support.

LAAC data remind us that stroke risk in atrial fibrillation is not eliminated with closure. Contemporary anticoagulants carry a low risk of non major bleeding, a threshold that may fall further with emerging factor XI agents. Outcomes with WATCHMAN FLX appear favorable in selected lower risk patients, but potentially at the cost of higher stroke rates. Caution remains warranted before committing low bleeding risk patients to a permanent implant.

IVUS in PCI continues to show incremental benefit, yet outcomes in high risk PCI appear similar with or without imaging. This is not unexpected. Operators who routinely use IVUS tend to internalize principles of sizing and optimization. The more relevant comparison may be between low and high IVUS utilization, and between early career operators with robust imaging training and those without.

Catheter directed thrombolysis using EKOS system remains a sound option for intermediate risk pulmonary embolism when bleeding risk is acceptable, as supported by HI-PEITHO trial. While recent momentum has favored mechanical thrombectomy, it is reassuring to see continued support for CDT.

In patients undergoing TAVI, routine PCI of stable coronary disease is not supported. A selective approach focused on lesions with clear prognostic relevance is more appropriate, though the field has yet to precisely define this threshold.

AngioFFR is emerging as a practical method for ischemia assessment. Wire based physiology remains reliable and essential in specific settings. However, unlike wire based tools, angiography derived algorithms will continue to evolve with iterative learning, much like CT-FFR, and are likely to become increasingly central in routine practice.

ORBITA-CTO trial adds an important perspective. CTO PCI offers meaningful improvement in symptoms and quality of life in carefully selected patients. There is a clear signal of benefit. For patients with refractory angina despite optimal therapy, CTO PCI should be viewed as a legitimate escalation strategy.

@ACCinTouch @SCAI @TCTMD @RowanVirtuaSOM @SVM_tweets @TCTConference @TCT_ME_ @American_Heart @AHANewJersey @AHAPennsylvania @mmamas1973 @mirvatalasnag @djc795 @MichaelMegalyMD @GPAngioClub

Amartya Kundu

@AmartyaKundu_MD

Mar 30

Evandro Martins F. MD

@evandrofilhobr

Mar 29

16/16
🏷️ Tagging the CTO community for discussion 👇

✍️ Authors: @dr_skhan1 @rallamee @DrKeeble @EssexCTC

@esbrilakis @DFCapodanno @DrMarthaGulati @CtoDemon @CtoEuro @ctoessentials @cto_chip_japan @tobicongress @realarainmd @SaadGhummanMD @DrOzanDemir @DrAsifQasim @Hragy @mmamas1973 @DrBIqbal @ACCinTouch
What are your thoughts? 🧵👆